Welcome to our dedicated page for Protagonist Therapeutics SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protagonist Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protagonist Therapeutics's regulatory disclosures and financial reporting.
Protagonist Therapeutics Chief Financial Officer Asif Ali reported multiple stock transactions on January 27, 2026. He exercised stock options for 16,000 common shares at $19.19 and 12,000 shares at $12.17, then sold 28,000 shares at a weighted average price of $83.13 and 18,203 shares at $83.14. After these transactions, he directly owned 60,320 common shares. The exercised options relate to grants from April 18, 2022 and January 16, 2023, which vest over time subject to his continued service.
Protagonist Therapeutics Chief Medical Officer Arturo Molina reported multiple stock option exercises and share sales. On January 26 and 27, 2026, he exercised a total of 10,000 stock options at an exercise price of $8.04 per share and acquired the same number of common shares.
He then sold 5,000 shares on each of January 26 and 27 at weighted average prices of $82.28 and $82 per share, and earlier sold 13,151 shares on January 23, 2026 at a weighted average price of $82.42 per share. After these transactions he directly owned 84,115 common shares and 65,971 stock options, with the option grant originally covering 127,500 shares and vesting through November 7, 2026.
Asif Ali has filed a notice of proposed sale of 46,203 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $3,841,128.28, to be sold on the NASDAQ on or about January 27, 2026.
The filing notes that 62,515,666 shares of the same class were outstanding, providing context for the size of the planned sale. In the prior three months, Asif Ali sold 8,588 common shares for gross proceeds of $708,327.08. The form includes a representation that the seller is not aware of undisclosed material adverse information about the issuer’s operations.
Arturo Molina has filed a Rule 144 notice to sell 5,000 shares of PTGX common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $410,000. These shares were acquired on 01/27/2026 via a stock option exercise paid in cash for 5,000 shares. The notice lists 62,515,666 common shares outstanding and anticipates sale on 01/27/2026 on the NASDAQ market.
Over the prior three months, the same seller reported additional PTGX common stock sales, including 9,514 shares on 01/20/2026 for $784,702.35 and 13,151 shares on 01/23/2026 for $1,097,115.60. The notice also records sales of 5,000 shares on 01/26/2026 for $411,396.00 and 2,712 shares on 11/18/2025 for $229,896.24. By signing, the seller represents not knowing any undisclosed material adverse information about PTGX.
Arturo Molina filed a Rule 144 notice to sell 5,000 shares of common stock of the PTGX issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $411,396.00. The shares were acquired on 01/26/2026 via a stock option exercise from the issuer and paid for in cash the same day.
The notice also lists recent activity over the prior three months, including sales of 2,712 shares on 11/18/2025 for gross proceeds of $229,896.24, 13,151 shares on 01/23/2026 for $1,097,115.60, and 9,514 shares on 01/20/2026 for $784,702.35. The issuer reports 62,515,666 shares of this class outstanding, and the planned sale is to be executed on or about 01/26/2026 on the NASDAQ exchange.
Arturo Molina has filed a notice of proposed sale under Rule 144 to sell 13,151 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $1,097,115.60 and an approximate sale date of 01/23/2026. The table shows 62,515,666 common shares outstanding as a baseline figure.
The shares to be sold were acquired as restricted stock from the issuer in several grants on 11/15/2025 and 01/15/2026. Over the past three months, Molina has already sold 2,712 common shares on 11/18/2025 for gross proceeds of $229,896.24 and 9,514 common shares on 01/20/2026 for gross proceeds of $784,702.35. By signing, the seller represents not knowing any undisclosed material adverse information about the issuer's operations.
PTGX has a planned sale of 108,273 common shares under Rule 144, with an aggregate market value of $9,162,061. The shares are to be sold through J.P. Morgan Securities LLC on the Nasdaq, with an approximate sale date of 01/23/2026, and the filing notes 62,515,666 shares of this class outstanding.
The person for whose account the securities will be sold acquired these shares directly from the issuer on 01/23/2026 via cash option exercises in two transactions of 30,000 and 78,273 shares. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Protagonist Therapeutics Chief Medical Officer Arturo Molina reported a sale of company stock. On January 20, 2026, he sold 9,514 shares of Common Stock at a price of $82.48 per share. The filing explains that this sale was made to cover the tax withholding obligation incurred when restricted stock units settled, meaning the transaction was tied to taxes rather than an open-market portfolio decision. After this sale, Molina beneficially owned 97,266 shares of Protagonist Therapeutics common stock in direct form.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported a sale of company common stock in a Form 4 filing. On January 20, 2026, he sold 34,438 shares of Protagonist Therapeutics common stock at a price of $82.48 per share, reported as a direct ownership transaction.
According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was tied to an equity award rather than an open-market discretionary sale of his broader holdings. After this transaction, Patel directly beneficially owned 580,505 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali reported a sale of common stock in a Form 4 filing. On January 20, 2026, he sold 8,588 shares of Protagonist Therapeutics common stock at a price of $82.48 per share. According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was connected to equity compensation rather than a discretionary open-market sale. After this transaction, Ali beneficially owns 78,077 shares of the company’s common stock directly.